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For the last decades, antibacterial research and development has focused
on drugs that kill bacteria or inhibit their growth by interfering with essential
cellular processes. Conventional antibiotics inherently impose selective
pressure on bacteria and microbial drug resistance constitutes a complex
global public health challenge. In this project we aim to design small
molecules that potentiate the effect of existing antibiotics. More specifically,
we want to synthesize compounds that target virulence factors and biofilm
formation in Staphylococcus aureus and hence sensitize ‘golden staph’
towards antibiotic treatment. With careful consideration, we believe that
these “antivirulence” drugs have a lower propensity to select for resistance.
Recently, Kiran et al. discovered hamamelitannin (HAM, Figure): a small
molecule that prevents biofilm formation and increases the susceptibility of
S. aureus towards vancomycin treatment. HAM is a natural substance
isolated from the witch hazel (Hamamelis virginiana) and represents an
interesting lead for further optimization. However, the stability and activity
of this natural molecule are not optimal. Hit-to-lead optimisation of HAM
led to the identification of compound 2, a metabolically stable derivative
with potent in vitro activity (0.389 μM), exceptional activity in a C. elegans
infection model and a murine mastitis model, while lacking cytotoxicity
against MRC-5 lung fibroblast cells.
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